Medicines
|
Blister-Packaged Tablets:
|
Diethylcarbamazine (DEC) for lymphatic filariasis and tropical pulmonary eosinophilia
100 mg tiny tablet
|
Ivermectin (IVM) for onchocerciasis, lymphatic filariasis, scabies, strongyloidiasis, mansonelliasis, and malaria transmission
3 mg dissolvable
|
|
Albendazole (ALB) for soil transmitted helminths (ascariasis, trichuriasis, and hookworm infection), lymphatic filariasis, oesophagostomiasis, and strongyloidiasis
400 mg chewable
|
|
Benzathine Penicillin (BPG) for congenital syphilis, rheumatic heart disease, erysipelas, yaws, and pinta
1.2M U IM and 2.4 U IM vials
|
Blister-Packaged Soft Gelatin Capsules:
|
Vitamin A (Vit A) for blindness and related mortality, respiratory disease, and other infections
100,000 IU and 200,000 IU liquid
|
The usual approach to community-based mass drug administration is for tablets to be distributed from shared bottles without labels or instructions. As a result, patients have a lack of trust and effective coverage is poor. Today, Bend Biomedical blister-packaged medicines are attractive for both low- and middle-income countries. Our packaging model can be used to provide critically needed medicines for neglected populations around the world.
Community-based mass drug administration with our blister-packaged albendazole or ivermectin tablets is an opportune time to distribute a high-dose vitamin A capsule to children under five.
Most of our disease targets are for “Neglected Tropical Diseases,” a group of infections that are common in the tropics and subtropics. These diseases are poverty-related and impair or permanently disable millions of people every year, often making it difficult to be productive in school, to marry, and to earn a living. They often cause life-long physical pain and social stigmatization.
We participate in a process known as World Health Organization (WHO) prequalification of medicines, a service provided by WHO to assess the quality, safety and efficacy of medicinal products. Only essential medicines qualify. Countries are now expressing a preference for WHO prequalified generics.
Drugs and diseases are listed for informational purposes only. Consult your local medical authority for advice.
Sources
Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva: World Health Organization; 2017. 9789241550161-eng.
Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: World Health Organization; 2016 (updated 2020). 9789241510011-eng.
Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017. 9789241550116-eng.
The Global elimination of congenital syphilis: rationale and strategy for action. Geneva, World Health Organization, 2007. 9789241595858_eng.
Guideline: Vitamin A supplementation in infants and children 6-59 months of age. Geneva, World Health Organization, 2011. 9789241501767-eng.